Leen Kawas, Alzheimer’s CEO who re­signed in da­ta ma­nip­u­la­tion scan­dal, re­turns to launch in­vest­ment firm with bil­lion­aire

Leen Kawas, the start­up founder and CEO who unit­ed in­vestors be­hind a dark­horse ap­proach to treat­ing Alzheimer’s be­fore re­sign­ing last year in a da­ta ma­nip­u­la­tion scan­dal, is back.

Kawas and bil­lion­aire pri­vate eq­ui­ty in­vestor Richard Kayne an­nounced on Fri­day the launch of Pro­pel Bio, a new in­vest­ment firm fo­cused on “com­pa­nies at var­i­ous stages across the life sci­ence space.”

The pair of­fered few oth­er de­tails about the new firm, and a spokesper­son said that nei­ther would speak on the record or com­ment be­yond the re­lease “to com­ply with SEC reg­u­la­tions.” An SEC fil­ing Fri­day in­di­cat­ed the com­pa­ny planned to raise $150 mil­lion, but did not list any funds raised to date.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER